HIV-tuberculosis coinfection: Difference between revisions
From IDWiki
(Created page with "== Management == === Latent Tuberculosis Infection === * When using isoniazid monotherapy, can use any HIV medication * When using rifampin or rifapentine, need...") Â |
(→â€)  |
||
(3 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
− | == |
+ | ==Management== |
− | === |
+ | ===Latent Tuberculosis Infection=== |
− | * |
+ | *When using [[isoniazid]] monotherapy, can use any HIV medication |
− | * |
+ | *When using [[rifampin]] or [[rifapentine]], need to check for drug-drug interactions |
− | === |
+ | ===Active Tuberculosis=== |
− | * |
+ | *[[Rifampin]] is a core antimicrobial for tuberculosis and should be given priority in drug-drug interactions |
− | * |
+ | *NRTIs do not require any adjustment, INSTIs and NRTIs often need dose adjustment, and PIs are usually contraindicated |
+ | *Regimens that minimize drug-drug interactions: |
||
− | ** |
+ | **[[Efavirenz]] 600 mg PO daily or [[raltegravir]] 400 mg PO bid, combined with [[abacavir]]/[[lamivudine]] or [[tenofovir disoproxil fumarate]]/[[emtricitabine]] |
⚫ | |||
+ | **[[Tenofovir disoproxil fumarate]]/[[emtricitabine]] + [[efavirenz]] |
||
⚫ | |||
+ | **[[Tenofovir disoproxil fumarate]]/[[emtricitabine]] + double [[raltegravir]] |
||
⚫ | |||
+ | **[[Abacavir]]/[[lamivudine]] with BID [[dolutegravir]] |
||
⚫ | |||
+ | **[[Tenofovir alafenamide]] may or may not be affected by [[rifampin]] |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
[[Category:HIV]] |
[[Category:HIV]] |
Latest revision as of 14:49, 5 January 2022
Management
Latent Tuberculosis Infection
- When using isoniazid monotherapy, can use any HIV medication
- When using rifampin or rifapentine, need to check for drug-drug interactions
Active Tuberculosis
- Rifampin is a core antimicrobial for tuberculosis and should be given priority in drug-drug interactions
- NRTIs do not require any adjustment, INSTIs and NRTIs often need dose adjustment, and PIs are usually contraindicated
- Regimens that minimize drug-drug interactions:
- Efavirenz 600 mg PO daily or raltegravir 400 mg PO bid, combined with abacavir/lamivudine or tenofovir disoproxil fumarate/emtricitabine
- Tenofovir disoproxil fumarate/emtricitabine + efavirenz
- Tenofovir disoproxil fumarate/emtricitabine + double raltegravir
- Abacavir/lamivudine with BID dolutegravir
- Tenofovir alafenamide may or may not be affected by rifampin
- Timing
- Start TB treatment immediately
- If not already on HIV treatment:
- CD4 count <50 cells/mm3: start HIV treatment as soon as possible, and within 2 weeks of TB treatment
- CD4 count ≥50 cells/mm3: start HIV treatment within 8 weeks of TB treatment
- Pregnancy, regardless of CD4: start as soon as feasible, to prevent transmission
- With tuberculous meningitis, generally defer to 8 weeks, or monitor closely when starting early